A preclinical study showed that the use of an BRCA2-targeting antisense oligonucleotide, in combination with olaparib, sensitized numerous human cancer cell lines to this drug, thus increasing the incidence of chromosomal translocations and aneuploidies and preventing resistance to olaparib (and in general to PARP-1 inhibitors) in various tumor cell populations [77]. This evidence concerns the gene BRCA2 and cancer.